As there have been some confusions regarding Mannkind's recent commercial partnership with Sanofi in launching it's lead drug Afrezza, the super rapid acting insulin, as early as in the first quarter of 2015. In contrast to the market's negativity, the partnership profit splits 35 percent for MannKind Corporation (NASDAQ: MNKD) and 65 percent for Sanofi SA ADR (NYSE:SNY) is actually highly favorable given that other companies in similar boat to MannKind would have gotten much less. So I don't see why the critics are frowning upon this deal. With Sanofi's elite experts in diabetes/pharmaceuticals, seeing true merits in Afrezza, which enables the company to choose Afrezza, as the replacement for Lantus' over $6 billion annual revenues when Lantus goes generic soon.

Sanofi also partnered up with Regeneron for another revolutionary LDL-cholesterol lowering drug alirocumab, which showed its phase 3 data having better efficacy and similar safety profile to Lipitor – a blockbuster that recognized more than $12 billion for Pfizer.

Source: Regeneron

Read More at Retail Investor 360